About Nucleix
Nucleix is a company based in Rehovot (Israel) founded in 2008.. Nucleix has raised $85.5 million across 9 funding rounds from investors including BlackRock, Orbimed and RA Capital. Nucleix offers products and services including Bladder EpiCheck and Lung EpiCheck. Nucleix operates in a competitive market with competitors including Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
- Headquarter Rehovot, Israel
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$85.5 M (USD)
in 9 rounds
-
Latest Funding Round
$22 M (USD), Series C
Dec 30, 2021
-
Investors
BlackRock
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nucleix
Nucleix offers a comprehensive portfolio of products and services, including Bladder EpiCheck and Lung EpiCheck. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Non-invasive test for monitoring bladder cancer recurrence.
Blood test for early detection of lung cancer in high-risk individuals.
Unlock access to complete
Unlock access to complete
Funding Insights of Nucleix
Nucleix has successfully raised a total of $85.5M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $22 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series C — $22.0M
-
First Round
First Round
(16 Jun 2014)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Series C - Nucleix | Valuation | Sands Capital | |
| Apr, 2021 | Amount | Grant - Nucleix | Valuation |
investors |
|
| Apr, 2021 | Amount | Series C - Nucleix | Valuation | RA Capital Management |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nucleix
Nucleix has secured backing from 11 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include BlackRock, Orbimed and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
LYFE Capital is recognized as a premier healthcare investment platform.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nucleix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nucleix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nucleix Comparisons
Competitors of Nucleix
Nucleix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Circulating tumor DNA is screened for early cancer detection.
|
|
| domain | founded_year | HQ Location |
Provider of DNA sequencing for cancer detection
|
|
| domain | founded_year | HQ Location |
Provider of cell-free cancer liquid biopsy test
|
|
| domain | founded_year | HQ Location |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nucleix
Frequently Asked Questions about Nucleix
When was Nucleix founded?
Nucleix was founded in 2008 and raised its 1st funding round 6 years after it was founded.
Where is Nucleix located?
Nucleix is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.
Is Nucleix a funded company?
Nucleix is a funded company, having raised a total of $85.5M across 9 funding rounds to date. The company's 1st funding round was a Series C of $55M, raised on Jun 16, 2014.
What does Nucleix do?
Nucleix was founded in 2008 in Rehovot, Israel, within the biotechnology sector focused on oncology diagnostics. Non-invasive tests for cancer detection are created by leveraging DNA methylation patterns through proprietary biomarker assays. The initial product, Bladder EpiCheck, is applied for bladder cancer diagnosis. Tests for colorectal and lung cancer have also been developed to support early detection in clinical settings.
Who are the top competitors of Nucleix?
Nucleix's top competitors include Guardant Health, GRAIL and BillionToOne.
What products or services does Nucleix offer?
Nucleix offers Bladder EpiCheck and Lung EpiCheck.
Who are Nucleix's investors?
Nucleix has 11 investors. Key investors include BlackRock, Orbimed, RA Capital, European Union, and DSC Investment.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.